OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gogishvili on the Rationale for the EMPOWER-Lung 3 Trial in NSCLC

October 26th 2021

Miranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.

Dr. Randall on Initial Considerations When Treating Patients With Desmoid Tumors

October 26th 2021

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Dr. Modi on the Utility of BTK Inhibitors in CLL

October 26th 2021

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

October 26th 2021

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Dr. Shroff on Unmet Needs in Advanced Biliary Tract Cancer

October 26th 2021

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ Cancer

October 25th 2021

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 25th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in Glioblastoma

October 25th 2021

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

Dr. Heimbach on the Need for Multidisciplinary Care in HCC

October 25th 2021

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

Dr. Wierda on Future Research Directions With MRD in CLL

October 25th 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Shah on the Potential Utility of NK Cells in Multiple Myeloma

October 25th 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

October 25th 2021

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer

October 25th 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Dr. Abutalib on Recent Updates in CLL

October 25th 2021

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

October 22nd 2021

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC

October 22nd 2021

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC

October 22nd 2021

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

Dr. Wierda on Ongoing Research Efforts Examining Fixed-Duration Strategies in CLL

October 21st 2021

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Dr. Thompson on the Rationale for the BRUIN Study in Richter Transformation

October 21st 2021

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Shroff on the Importance of Targeted Therapy in Advanced Biliary Tract Cancer

October 21st 2021

Rachna T. Shroff, MD, discusses the importance of targeted therapy in advanced biliary tract cancer.